Oncology Services

Innovative pre-clinical solutions for in vivo cancer modeling. We specialize in the production of over 450 clinically relevant patient-derived xenograft models genetically characterized for distribution and provide efficacy testing services to advance your cancer research and enable the selection of cancer immunotherapeutics.

Request a Quote

Advanced Clinically Relevant Cancer Models

We are committed to providing you with the most innovative pre-clinical models to delineate the mechanisms underlying disease and enable you to select efficacious drugs to treat individualized targeted tumor types.

  • PDX Models are genetically characterized and at earlier passage numbers than any other PDX collection available today. Our collection includes readily available, off-the-shelf PDX LiveTMtumor model cohorts allowing rapid study turnaround and faster decision-making.
  • Humanized Mice are immediately available to ship to your facility for subsequent engraftment with cancer cell lines or tissues for immuno-oncology research and development.

Efficacy Studies Accelerating Drug Discovery

We offer customizable study designs, direct access to a comprehensive collection of patient-derived-xenograft (PDX) mouse models, cancer cell line xenografted models, and immuno-oncology platforms humanized with both PDX and human immune systems to test the effectiveness of novel or existing immunotherapeutic compounds.

Transforming Research

Developing the most sophisticated models and applications, we are committed to providing you with the tools that propel effective treatments for cancer. Our mice and service solutions combine innovation, reliability,and commitment to customer service to offer you the most clinically-relevant mouse models and precision services. Through our industry-leading animal health and genetic stability programs, our team of study directors and mouse husbandry professionals ensures that mouse strains you receive are uniform, well-characterized, and have the highest health quality available.